- Home
- SPRO vs RNTX Comparison
SPRO vs RNTX Comparison
Compare SPRO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RNTX
- Stock Information
- Founded
- SPRO 2013
- RNTX 2001
- Country
- SPRO United States
- RNTX United States
- Employees
- SPRO N/A
- RNTX N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- RNTX Health Care
- Exchange
- SPRO Nasdaq
- RNTX Nasdaq
- Market Cap
- SPRO 45.7M
- RNTX 44.2M
- IPO Year
- SPRO 2017
- RNTX N/A
- Fundamental
- Price
- SPRO $0.72
- RNTX $1.77
- Analyst Decision
- SPRO Buy
- RNTX
- Analyst Count
- SPRO 4
- RNTX 0
- Target Price
- SPRO $5.00
- RNTX N/A
- AVG Volume (30 Days)
- SPRO 118.7K
- RNTX 26.9K
- Earning Date
- SPRO 03-27-2025
- RNTX 05-14-2025
- Dividend Yield
- SPRO N/A
- RNTX N/A
- EPS Growth
- SPRO N/A
- RNTX N/A
- EPS
- SPRO N/A
- RNTX N/A
- Revenue
- SPRO $47,977,000.00
- RNTX N/A
- Revenue This Year
- SPRO N/A
- RNTX N/A
- Revenue Next Year
- SPRO N/A
- RNTX N/A
- P/E Ratio
- SPRO N/A
- RNTX N/A
- Revenue Growth
- SPRO N/A
- RNTX N/A
- 52 Week Low
- SPRO $0.70
- RNTX $1.61
- 52 Week High
- SPRO $1.81
- RNTX $7.42
- Technical
- Relative Strength Index (RSI)
- SPRO 38.19
- RNTX N/A
- Support Level
- SPRO $0.75
- RNTX N/A
- Resistance Level
- SPRO $0.80
- RNTX N/A
- Average True Range (ATR)
- SPRO 0.05
- RNTX 0.00
- MACD
- SPRO 0.00
- RNTX 0.00
- Stochastic Oscillator
- SPRO 9.09
- RNTX 0.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.